Boehringer Ingelheim Launches ‘Why Wait in IPF?’ Campaign, Raising Awareness of Early Diagnosis

On last week’s Rare Disease Day, held Feb. 28, Boehringer Ingelheim launched a new campaign titled “Why Wait in IPF?” to raise awareness about the importance of early diagnosis of idiopathic pulmonary fibrosis (IPF) and treatment with anti-fibrotic drugs. Even though international guidelines recommend treatment with anti-fibrotic drugs…